What is Mounjaro used for in the UK?

What does Mounjaro actually do inside the body?

Tirzepatide acts on two receptors simultaneously: the glucose-dependent insulinotropic polypeptide receptor (GIP) and the glucagon-like peptide-1 receptor (GLP-1). Activating both pathways at once slows the rate at which food leaves the stomach, signals the brain that you have eaten enough, and helps the pancreas release insulin in response to meals. The result, clinically, is a meaningful reduction in calorie intake and, in people with type 2 diabetes, improved blood-sugar control.

This dual mechanism is what distinguishes tirzepatide from older GLP-1 medicines, which activate only the GLP-1 pathway. Whether that difference translates into better outcomes for a specific individual is a clinical question, it depends on their health history, other medicines they take, and how they respond to treatment. If you are new to this medicine and want to understand the basics first, our page explaining what Mounjaro is gives a clear starting point before reading further. You can also read more about the science behind the molecule on our tirzepatide overview page.

The NHS medicines page for tirzepatide explains how the medicine works alongside its full side-effect profile, and is worth reading before starting treatment or asking your prescriber questions about it.

Which conditions is Mounjaro licensed to treat?

In the UK, Mounjaro is currently licensed for two conditions. The first is weight management: adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health problem (such as high blood pressure, high cholesterol, prediabetes, type 2 diabetes, or obstructive sleep apnoea), can be considered for it alongside a reduced-calorie diet and increased physical activity. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance.

The second licensed use is glycaemic control in type 2 diabetes, where tirzepatide has been used alone or combined with other diabetes medicines depending on the patient's treatment history. These two licences can overlap (someone with type 2 diabetes and obesity may use Mounjaro for both purposes at once) but the prescriber decides how to frame the treatment and which clinical guidelines apply.

A question our prescribers hear most weeks is whether someone can use Mounjaro solely for cosmetic weight loss. The short answer is no: the MHRA has been clear that GLP-1 medicines are not assessed or licensed for cosmetic purposes, and the eligibility criteria exist to make sure the health benefit justifies the clinical risks involved. Our detailed page on tirzepatide for weight loss sets out the eligibility requirements fully.

It is also worth knowing that Mounjaro is not the only name tirzepatide has carried. If you have come across references to the US brand, our page on what Mounjaro was originally used for covers the history of the molecule's development from its diabetes origins.

How significant is the evidence behind Mounjaro's weight-management use?

The SURMOUNT clinical programme, which included thousands of adults with obesity, produced some of the largest weight-loss results ever recorded in a licensed medicine trial. In SURMOUNT-1 (a 72-week randomised trial involving 2,539 adults with obesity but without type 2 diabetes) participants on the 15mg maintenance dose lost an average of around 20–21% of body weight. That figure comes from the trial published in the New England Journal of Medicine and is the basis on which NICE recommended tirzepatide for NHS use in December 2024.

These are trial averages. Individual results depend on adherence, starting weight, diet, activity levels and other health factors. The treatment is not a standalone solution; the licence specifically requires it to be used alongside dietary change and increased movement. Thinking about whether those results are realistic for your situation is worth raising with a prescriber rather than treating the headline figure as a personal forecast.

For context on how private treatment is priced in the UK, our page on Eli Lilly's UK price changes explains what has happened to list prices since September 2025 and what that means for private patients. Those considering whether to start treatment can also explore our weight-loss treatment overview for a fuller picture of the options available.

What Mounjaro is not used for, and why that distinction matters

Mounjaro is not licensed for use in people under 18, during pregnancy or breastfeeding, or for those actively trying to conceive. It is also not recommended where there is a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and anyone with a history of pancreatitis should discuss this carefully with a prescriber before considering it.

On the question of long-term use, the picture is still developing. Mounjaro carries the MHRA's Black Triangle (▼), indicating it is subject to additional monitoring because post-marketing data continues to accumulate. If you are thinking about what extended treatment looks like, our page on Mounjaro and long-term use covers what is currently known.

Finally, Mounjaro is not a medicine you can obtain without a valid prescription from a registered prescriber. Any seller offering tirzepatide without a clinical assessment is operating outside UK law. If you ever want to check whether an online pharmacy is properly registered, the GPhC pharmacy register is publicly searchable and takes less than a minute to use. At nume, every order goes through the same clinical process: a GPhC-registered Independent Prescriber reads your consultation personally before any treatment is approved or dispatched.

If you'd like to find out whether you're a suitable candidate, you're welcome to speak to our prescribers through a free consultation.